Navigation Links
InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
Date:11/17/2011

TEL-AVIV, Israel, Nov. 17, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology, today announced that Sol J. Barer, Ph.D., a current member of the Company's board of directors and the former Chairman, and CEO of Celgene Corporation, has been elected the Chairman of InspireMD's Board of Directors, effective immediately. InspireMD thanks Asher Holzer for his contributions as chairman and leading the Company to its current successful stage. Mr. Holzer will continue as President of the Company and a member of the Board of Directors.  

Dr. Barer commented, "Since I joined the Board of Directors mid-year, I have become increasingly impressed with the Company's potential and am very pleased to have been asked to take the Chairman's role. I look forward to working with the Board and management in developing products and securing regulatory approval for life-saving products and positioning the Company for enhanced shareholder value."

Dr. Barer has more than 30 years experience with publicly traded biotechnology companies. In 1980, he was with Celanese Research Company when he formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer spent 18 years leading Celgene, holding the positions of president, COO and Chairman and CEO during different periods, culminating with his tenure as Celgene's Executive Chairman before retiring in June of 2011. Celgene's market capitalization at his retirement was approximately $27 billion. Dr. Barer serves on the Board of several companies including: Amicus Therapeutics, Inc., Aegerion Pharmaceuticals, Inc., ContraFect Corp., Cerecor Corp and Edge Therapeutics, Inc. He serves as Chairman of BioNJ Inc., the 300 company biotechnology organization of New Jersey, as Chairman of the Governor of New Jersey's UMDNJ Advisory Committee and advises
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
2. InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco
3. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
4. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
5. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
6. County of Los Angeles Selects Netsmart to Provide Comprehensive Behavioral Health Information System
7. The American Ceramic Society selects Marshall, Niihara as 2011 Distinguish Life Members
8. H. D. Smith Selects IT Industry Executive David Guzman as CIO
9. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
10. EdgeBio Selects Calipers Sample Preparation Suite for High Throughput and Benchtop Sequencing Workflows
11. St. Lukes Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... (OTCBB:GNBT) today announced that it has entered into ... to which UHN,s Centre for Molecular Design and ... refinement project.  The goal of the project is ... the Company,s proprietary buccal insulin spray product, thereby ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
(Date:9/22/2014)... The US markets on Friday, ... the Dow Jones Industrial Average finished at 17,279.74, up ... 0.30%. The S&P 500 finished the session 0.05% lower ... ten sectors finished on a positive note. The S&P ... 751.48, up 0.10%, with the index gaining 6.95% in ...
(Date:9/22/2014)... , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic products ... Robert Bazemore as Chief Operating Officer.  ... President and Chief Executive Officer, Robert will oversee ... lead program, sebelipase alfa for LAL Deficiency, and ...
Breaking Biology Technology:Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... interesting meeting took place this past week at the University ... The focus of the meeting was an opportunity to hear ... last annual BIO meetings in different cities, as a preview ... this Olympics of Biotechnology meeting comes to Chicago in April, ...
... hit a nerve. , , I heard from a number ... 2.0 is spelled b-u-b-b-l-e, and who want none of it. As ... use a healthy dose of caution to prevent the heavy Kool-Aid ... group. , ,Indeed, in dozens of conversations with start-ups seeking a ...
... and after its recent redesign The Internal Revenue Service ... well as tweaking its search engine to hopefully make it easier ... keeping roughly the same design since mid-2002, the IRS decided to ... Among other features, the site has links to the most-requested publications ...
Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6Can we prevent Web 2.0 from being a bubble? 2Can we prevent Web 2.0 from being a bubble? 3
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... significantly less likely to report taking iron supplements before ... who are developing normally, a study by researchers with ... iron intake was associated with a five-fold greater risk ... 35 or older at the time of the child,s ... as obesity hypertension or diabetes. , The research is ...
(Date:9/21/2014)... at the University of California, San Diego, have developed ... that control the activity of genes based on sequences ... from its application to human embryonic cells in a ... 21. , "All of our cells have the same ... said John Whitaker, lead author of the report. "Skin ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
... Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the ... approved,the scheme of arrangement between Shire plc and ... which becomes effective on 23 May 2008,results in ... SHP,NASDAQ: SHPGY) becoming the new holding company for ...
... CORVALLIS, Ore. An international team of scientists surveying ... Coast of North America has discovered for the first ... miles of the shoreline, raising concern for marine ecosystems ... an Oregon State University research vessel, also discovered that ...
... called FIGLA cause premature ovarian failure in at least a ... from Baylor College of Medicine in Houston and Shandong University ... the American Journal of Human Genetics. We hope to ... genes associated with this problem to find biomarkers in blood ...
Cached Biology News:Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3Oocyte-specific gene mutations cause premature ovarian failure 2
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Biology Products: